They work by inhibiting the body's blood vessel formation close to the tumour, which is thereby cut off from oxygen and nutrient supply.
Up to now, the researchers at Aarhus University in Denmark have tested some of the antibodies on mice and, in the laboratory, they have succeeded in using them to stop the development of malignant tumours.
"The antibodies we've found prevent a cancer tumour from growing. They appear to work perfectly in the laboratory, and this means, of course, that they've got incredibly interesting therapeutic potential that we'll investigate further. However, we're still quite early in the experimental stage," said Associate Professor Peter Kristensen.
A cancer tumour deprived of oxygen and nutrients becomes dormant and is thereby made harmless. If it receives a supply from the bloodstream, however, it grows and spreads, and the researchers appear to be able to prevent this deadly process.
A small number of therapeutic antibodies already exist, some of which have the same effect as the antibodies developed by the researchers. However, the existing antibodies are extremely expensive to produce.
The new antibodies are easier to extract, and they also appear to be more effective because they hit other - and possibly stronger - signal molecules from the cancer cells.
The researchers isolated their antibodies from a library consisting of billions of different antibodies, and they subsequently analysed the ability of the individual antibodies to inhibit blood vessel formation.
This sounds like incredibly extensive laboratory work, and it would have been far from possible just a few years ago. However, they used a biological technology for this purpose that they developed.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
